IndustryCompany release

Caribou Biosciences reports $26.6M Q3 loss, plans to end CAR-T trials and weigh strategic options

🇺🇸 Caribou Biosciences, Inc. (CRBU) · Thu 05 Nov 2026

The gene-editing company says it will discontinue clinical development of vispa-cel and CB-011 and is exploring alternatives, including a merger or liquidation, after a difficult financing climate.

Caribou Biosciences reported a net loss of $26.6 million for the third quarter of 2026 in results published on 5 November. The company held $94.8 million in cash and securities at 30 September.

The results restated a decision taken by the board on 6 October to restructure the business and explore strategic alternatives. The options under consideration include a merger or a liquidation of the company.

As part of that plan, Caribou intends to discontinue clinical development of its two allogeneic CAR-T candidates. Vispa-cel was being developed for B-cell non-Hodgkin lymphoma, and CB-011 for multiple myeloma. The company cited a difficult financing environment as the reason.

The summary available does not set out the timetable for the review, the terms of any transaction, or how ongoing trial participants will be handled. These details were not provided, so they are not reported here.

What it means for your team

  • Teams involved in Caribou's vispa-cel or CB-011 studies should watch for formal notices on trial wind-down, including any regulator and ethics committee notifications.
  • Pharmacovigilance and clinical operations groups may need to plan for continued safety follow-up and data handling for participants already treated, once the company gives details.
  • Market-access and partnering teams tracking allogeneic CAR-T should treat both assets as no longer in active clinical development, pending any outcome of the strategic review.

Company's press release (SEC filing): Caribou Biosciences, Inc. ↗

Article written by VigiEye from the official source (Caribou Biosciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →